Potential of improving the treatment of tuberculosis through nanomedicine

Boitumelo Semete; Lonji Kalombo; Lebogang Katata; Paul Chelule; Laetitia Booysen; Yolandy Lemmer; Saloshnee Naidoo; Bathabile Ramalapa; Rose Hayeshi; Hulda S. Swai

doi:10.1080/15421406.2012.635531

Potential of improving the treatment of tuberculosis through nanomedicine

Boitumelo Semete, Lonji Kalombo, Lebogang Katata, Paul Chelule, Laetitia Booysen, Yolandy Lemmer, Saloshnee Naidoo, Bathabile Ramalapa, Rose Hayeshi, Hulda S. Swai

Research output: Contribution to conference › Paper

7 Citations (Scopus)

Abstract

Current treatment of tuberculosis is inadequate due to lengthy treatment course and drug-related toxicity. To address these setbacks, we developed a nanotechnology drug delivery system that can be administered in a single dose that maintains an active level of drug for at least a week. Polymeric poly(lactic-co-glycolic acid) nanoparticles of 200-300 nm were synthesized, with a drug encapsulation efficiency of 50-65% for isoniazid and rifampicin. The particles were taken up in vitro and in vivo and a slow release profile was observed in mice over 5 days. This study illustrates the feasibility of a sustained release system for tuberculosis treatment. © Taylor & Francis Group, LLC.

Original language	English
Pages	317-330
Number of pages	14
DOIs	https://doi.org/10.1080/15421406.2012.635531
Publication status	Published - 1 Jun 2012
Externally published	Yes
Event	Molecular Crystals and Liquid Crystals - Duration: 1 Jun 2012 → …

Conference

Conference	Molecular Crystals and Liquid Crystals
Period	01/Jun/12 → …

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/15421406.2012.635531

Cite this

@conference{cafdd962077b4082b94fb4a440914826,

title = "Potential of improving the treatment of tuberculosis through nanomedicine",

abstract = "Current treatment of tuberculosis is inadequate due to lengthy treatment course and drug-related toxicity. To address these setbacks, we developed a nanotechnology drug delivery system that can be administered in a single dose that maintains an active level of drug for at least a week. Polymeric poly(lactic-co-glycolic acid) nanoparticles of 200-300 nm were synthesized, with a drug encapsulation efficiency of 50-65% for isoniazid and rifampicin. The particles were taken up in vitro and in vivo and a slow release profile was observed in mice over 5 days. This study illustrates the feasibility of a sustained release system for tuberculosis treatment. {\textcopyright} Taylor & Francis Group, LLC.",

author = "Boitumelo Semete and Lonji Kalombo and Lebogang Katata and Paul Chelule and Laetitia Booysen and Yolandy Lemmer and Saloshnee Naidoo and Bathabile Ramalapa and Rose Hayeshi and Swai, {Hulda S.}",

year = "2012",

month = jun,

day = "1",

doi = "10.1080/15421406.2012.635531",

language = "English",

pages = "317--330",

note = "Molecular Crystals and Liquid Crystals ; Conference date: 01-06-2012",

}

TY - CONF

T1 - Potential of improving the treatment of tuberculosis through nanomedicine

AU - Semete, Boitumelo

AU - Kalombo, Lonji

AU - Katata, Lebogang

AU - Chelule, Paul

AU - Booysen, Laetitia

AU - Lemmer, Yolandy

AU - Naidoo, Saloshnee

AU - Ramalapa, Bathabile

AU - Hayeshi, Rose

AU - Swai, Hulda S.

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Current treatment of tuberculosis is inadequate due to lengthy treatment course and drug-related toxicity. To address these setbacks, we developed a nanotechnology drug delivery system that can be administered in a single dose that maintains an active level of drug for at least a week. Polymeric poly(lactic-co-glycolic acid) nanoparticles of 200-300 nm were synthesized, with a drug encapsulation efficiency of 50-65% for isoniazid and rifampicin. The particles were taken up in vitro and in vivo and a slow release profile was observed in mice over 5 days. This study illustrates the feasibility of a sustained release system for tuberculosis treatment. © Taylor & Francis Group, LLC.

AB - Current treatment of tuberculosis is inadequate due to lengthy treatment course and drug-related toxicity. To address these setbacks, we developed a nanotechnology drug delivery system that can be administered in a single dose that maintains an active level of drug for at least a week. Polymeric poly(lactic-co-glycolic acid) nanoparticles of 200-300 nm were synthesized, with a drug encapsulation efficiency of 50-65% for isoniazid and rifampicin. The particles were taken up in vitro and in vivo and a slow release profile was observed in mice over 5 days. This study illustrates the feasibility of a sustained release system for tuberculosis treatment. © Taylor & Francis Group, LLC.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84861548021&origin=inward

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=84861548021&origin=inward

U2 - 10.1080/15421406.2012.635531

DO - 10.1080/15421406.2012.635531

M3 - Paper

SP - 317

EP - 330

T2 - Molecular Crystals and Liquid Crystals

Y2 - 1 June 2012

ER -

Potential of improving the treatment of tuberculosis through nanomedicine

Abstract

Conference

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this